[{"id":"3bf414c0-2141-4ef6-8218-6aca96f23937","acronym":"CHECK'UP","url":"https://clinicaltrials.gov/study/NCT03412058","created_at":"2021-03-04T17:52:48.409Z","updated_at":"2025-02-25T13:52:30.402Z","phase":"","brief_title":"Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists","source_id_and_acronym":"NCT03412058 - CHECK'UP","lead_sponsor":"UNICANCER","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK negative","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK negative"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 670","initiation":"Initiation: 06/27/2018","start_date":" 06/27/2018","primary_txt":" Primary completion: 01/02/2024","primary_completion_date":" 01/02/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-20"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"412de90b-4e3b-4146-9e47-4f34d9a4603a","acronym":"QUILT-3.055","url":"https://clinicaltrials.gov/study/NCT03228667","created_at":"2021-01-18T15:56:08.764Z","updated_at":"2025-02-25T17:35:53.589Z","phase":"Phase 2","brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03228667 - QUILT-3.055","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" BRAF • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type","tags":["BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/11/2018","start_date":" 12/11/2018","primary_txt":" Primary completion: 08/31/2029","primary_completion_date":" 08/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-29"},{"id":"41be4368-ac8d-41a5-97f4-07c00abcbd42","acronym":"ADAPT-E","url":"https://clinicaltrials.gov/study/NCT04585477","created_at":"2023-03-02T18:01:37.004Z","updated_at":"2025-02-25T14:59:23.663Z","phase":"Phase 2","brief_title":"Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)","source_id_and_acronym":"NCT04585477 - ADAPT-E","lead_sponsor":"Stanford University","biomarkers":" PD-L1 • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive","tags":["PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion • EGFR expression • ALK rearrangement • ROS1 rearrangement • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2026","study_completion_date":" 12/30/2026","last_update_posted":"2025-01-28"},{"id":"4b3b972a-c804-49a8-a2d6-60b8eae4c32b","acronym":"KEYNOTE-C62","url":"https://clinicaltrials.gov/study/NCT05860296","created_at":"2023-05-16T17:06:31.720Z","updated_at":"2025-02-25T16:18:48.260Z","phase":"Phase 1/2","brief_title":"Testing Experimental Anti-cancer Drug SLC-391 with an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","source_id_and_acronym":"NCT05860296 - KEYNOTE-C62","lead_sponsor":"SignalChem Lifesciences Corporation","biomarkers":" PD-L1 • KRAS • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SLC-391"],"overall_status":"Recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 05/31/2023","start_date":" 05/31/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2028","study_completion_date":" 09/01/2028","last_update_posted":"2024-11-19"},{"id":"cc0e252d-323c-463e-9f6b-bb8fa47915a5","acronym":"KEYNOTE-A87","url":"https://clinicaltrials.gov/study/NCT03565445","created_at":"2021-01-18T17:32:45.491Z","updated_at":"2025-02-25T16:08:02.730Z","phase":"Phase 1","brief_title":"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03565445 - KEYNOTE-A87","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 03/27/2023","study_completion_date":" 03/27/2023","last_update_posted":"2024-11-01"},{"id":"4f7b2be7-d23d-40b8-a5c9-76b1850fdede","acronym":"","url":"https://clinicaltrials.gov/study/NCT04736173","created_at":"2021-02-03T16:02:06.319Z","updated_at":"2024-07-02T16:34:37.611Z","phase":"Phase 3","brief_title":"Study Comparing the Combination Domvanalimab and Zimberelimab With Pembrolizumab in Untreated Locally Advanced or Metastatic PD-L1-High Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04736173","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • Yutuo (zimberelimab) • domvanalimab (AB154) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 169","initiation":"Initiation: 02/08/2021","start_date":" 02/08/2021","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-06-06"},{"id":"15f2feeb-91bd-4d1e-8210-eb0dea4872da","acronym":"ARC-7","url":"https://clinicaltrials.gov/study/NCT04262856","created_at":"2021-01-18T20:42:57.527Z","updated_at":"2024-07-02T16:35:00.997Z","phase":"Phase 2","brief_title":"Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04262856 - ARC-7","lead_sponsor":"Arcus Biosciences, Inc.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yutuo (zimberelimab) • domvanalimab (AB154) • etrumadenant (AB928) • mitazalimab (ADC-1013)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 151","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-24"},{"id":"aa0bda28-21b1-44ee-bd83-6ab69706eeb9","acronym":"ARCHON-1","url":"https://clinicaltrials.gov/study/NCT03801902","created_at":"2021-01-18T18:47:37.181Z","updated_at":"2024-07-02T16:35:02.360Z","phase":"Phase 1","brief_title":"Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial","source_id_and_acronym":"NCT03801902 - ARCHON-1","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/28/2019","start_date":" 10/28/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-05-21"},{"id":"d6301067-2808-4a94-93a8-b79f89b34627","acronym":"POLARIS","url":"https://clinicaltrials.gov/study/NCT03433924","created_at":"2021-01-18T16:56:20.491Z","updated_at":"2024-07-02T16:35:12.642Z","phase":"","brief_title":"An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.","source_id_and_acronym":"NCT03433924 - POLARIS","lead_sponsor":"AstraZeneca","biomarkers":" PD-L1 • CD8","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 248","initiation":"Initiation: 05/18/2020","start_date":" 05/18/2020","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 03/27/2023","study_completion_date":" 03/27/2023","last_update_posted":"2024-03-27"},{"id":"c74db0f2-c326-4bee-b78b-ae95a71b7f43","acronym":"","url":"https://clinicaltrials.gov/study/NCT06036745","created_at":"2023-09-14T15:13:27.955Z","updated_at":"2024-07-02T16:35:15.933Z","phase":"Phase 2","brief_title":"Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen","source_id_and_acronym":"NCT06036745","lead_sponsor":"Shanghai Minimally Invasive Surgery Center","biomarkers":" PD-L1 • TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR • PD-L1 overexpression","tags":["PD-L1 • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • oxaliplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 07/01/2023","primary_completion_date":" 07/01/2023","study_txt":" Completion: 07/01/2026","study_completion_date":" 07/01/2026","last_update_posted":"2024-03-07"},{"id":"3ffca675-0273-4289-8d96-fecb734298cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05340309","created_at":"2022-04-22T14:53:46.319Z","updated_at":"2024-07-02T16:35:19.527Z","phase":"Phase 2","brief_title":"Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05340309","lead_sponsor":"University of Southern California","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 12/07/2025","primary_completion_date":" 12/07/2025","study_txt":" Completion: 12/07/2026","study_completion_date":" 12/07/2026","last_update_posted":"2024-02-13"},{"id":"64c0b82c-66f6-4d94-aa8b-d3aaadbb12dc","acronym":"ANV419-001","url":"https://clinicaltrials.gov/study/NCT04855929","created_at":"2023-07-03T20:09:06.191Z","updated_at":"2024-07-02T16:35:19.786Z","phase":"Phase 1","brief_title":"A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.","source_id_and_acronym":"NCT04855929 - ANV419-001","lead_sponsor":"Anaveon AG","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-12"},{"id":"8c1958cd-2fa0-49cb-b97d-e1e5f14806eb","acronym":"IMreal","url":"https://clinicaltrials.gov/study/NCT03782207","created_at":"2021-01-18T18:42:21.980Z","updated_at":"2024-07-02T16:35:21.363Z","phase":"","brief_title":"A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice","source_id_and_acronym":"NCT03782207 - IMreal","lead_sponsor":"Hoffmann-La Roche","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3040","initiation":"Initiation: 02/07/2019","start_date":" 02/07/2019","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-02-01"},{"id":"032935d4-55fb-42dd-9d89-56ed868d4ba8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03229278","created_at":"2021-01-18T15:56:22.342Z","updated_at":"2024-07-02T16:35:26.954Z","phase":"Phase 1","brief_title":"Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma","source_id_and_acronym":"NCT03229278","lead_sponsor":"Rutgers, The State University of New Jersey","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Vyglxia (troriluzole)"],"overall_status":"Completed","enrollment":" Enrollment 14","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 10/20/2022","primary_completion_date":" 10/20/2022","study_txt":" Completion: 10/30/2022","study_completion_date":" 10/30/2022","last_update_posted":"2023-12-06"},{"id":"283266c0-98f1-4b60-833a-2384b5517207","acronym":"","url":"https://clinicaltrials.gov/study/NCT05732948","created_at":"2023-02-17T15:00:52.460Z","updated_at":"2024-07-02T16:35:27.778Z","phase":"Phase 1","brief_title":"PD-1 Silent PSMA/PSCA Targeted CAR-T for the Treatment of Prostate Cancer","source_id_and_acronym":"NCT05732948","lead_sponsor":"Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd","biomarkers":" PD-L1 • PSCA","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 08/02/2018","start_date":" 08/02/2018","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-29"},{"id":"948ce245-2d81-4ea7-b158-871cd6b33204","acronym":"EXPLORE-PDL1","url":"https://clinicaltrials.gov/study/NCT02785562","created_at":"2021-01-18T13:39:55.044Z","updated_at":"2024-07-02T16:35:33.382Z","phase":"","brief_title":"Epidemiologic Multicenter Prospective Study in Advanced NSCLC (Non Small Cell Lung Cancer) Patients With PDL1 (Protein Death Ligand 1) Expression.","source_id_and_acronym":"NCT02785562 - EXPLORE-PDL1","lead_sponsor":"Groupe Francais De Pneumo-Cancerologie","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • PD-L1 negative","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 07/21/2016","start_date":" 07/21/2016","primary_txt":" Primary completion: 04/06/2020","primary_completion_date":" 04/06/2020","study_txt":" Completion: 04/06/2020","study_completion_date":" 04/06/2020","last_update_posted":"2023-10-17"},{"id":"9890b512-7ca3-4d21-83a6-d06d0be49182","acronym":"POD1UM-203","url":"https://clinicaltrials.gov/study/NCT03679767","created_at":"2021-01-18T18:02:39.202Z","updated_at":"2024-07-02T16:35:42.372Z","phase":"Phase 2","brief_title":"A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)","source_id_and_acronym":"NCT03679767 - POD1UM-203","lead_sponsor":"Incyte Corporation","biomarkers":" PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression","tags":["PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynyz (retifanlimab-dlwr)"],"overall_status":"Completed","enrollment":" Enrollment 121","initiation":"Initiation: 01/09/2019","start_date":" 01/09/2019","primary_txt":" Primary completion: 04/15/2021","primary_completion_date":" 04/15/2021","study_txt":" Completion: 06/28/2022","study_completion_date":" 06/28/2022","last_update_posted":"2023-07-21"},{"id":"c202d09f-4287-4463-8629-079b1034deac","acronym":"","url":"https://clinicaltrials.gov/study/NCT03156114","created_at":"2021-01-18T15:33:42.030Z","updated_at":"2024-07-02T16:35:44.324Z","phase":"Phase 1","brief_title":"This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.","source_id_and_acronym":"NCT03156114","lead_sponsor":"Boehringer Ingelheim","biomarkers":" EGFR • ALK • TMB • MSI","pipe":" | ","alterations":" PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type","tags":["EGFR • ALK • TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • TMB-H • MSI-H/dMMR • PD-L1 overexpression • EGFR wild-type • ALK wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ezabenlimab (BI 754091) • miptenalimab (BI 754111)"],"overall_status":"Completed","enrollment":" Enrollment 172","initiation":"Initiation: 06/13/2017","start_date":" 06/13/2017","primary_txt":" Primary completion: 03/09/2023","primary_completion_date":" 03/09/2023","study_txt":" Completion: 06/06/2023","study_completion_date":" 06/06/2023","last_update_posted":"2023-06-29"},{"id":"243efccb-300c-4ed6-9b43-4e854952fa8d","acronym":"SHARP","url":"https://clinicaltrials.gov/study/NCT05701176","created_at":"2023-01-27T17:59:53.242Z","updated_at":"2024-07-02T16:35:56.876Z","phase":"","brief_title":"A Clinical Imaging Study of the Changes in [18F]F-AraG Uptake Following Anti-PD-1 Therapy in Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05701176 - SHARP","lead_sponsor":"Amsterdam UMC, location VUmc","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PD-L1 overexpression • ALK mutation • EGFR negative"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 11/03/2022","start_date":" 11/03/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2023-01-27"},{"id":"ce01d2bf-6a3f-4213-ba1c-326fad2c144a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05394233","created_at":"2022-05-27T12:55:39.431Z","updated_at":"2024-07-02T16:36:09.706Z","phase":"Phase 2","brief_title":"Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC","source_id_and_acronym":"NCT05394233","lead_sponsor":"Sichuan Cancer Hospital and Research Institute","biomarkers":" EGFR","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tevimbra (tislelizumab-jsgr) • pemetrexed"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2022-05-27"},{"id":"cb81a7f0-6230-4db7-aec3-4ce329f6c3b1","acronym":"FAME","url":"https://clinicaltrials.gov/study/NCT03709147","created_at":"2021-01-18T18:11:04.899Z","updated_at":"2024-07-02T16:36:38.650Z","phase":"Phase 2","brief_title":"Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma","source_id_and_acronym":"NCT03709147 - FAME","lead_sponsor":"Marina Garassino","biomarkers":" ALK • ROS1 • STK11 • IGF1","pipe":" | ","alterations":" PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression","tags":["ALK • ROS1 • STK11 • IGF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression • ALK rearrangement • ROS1 rearrangement • STK11 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • metformin"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 10/30/2018","start_date":" 10/30/2018","primary_txt":" Primary completion: 09/10/2023","primary_completion_date":" 09/10/2023","study_txt":" Completion: 09/10/2023","study_completion_date":" 09/10/2023","last_update_posted":"2020-11-16"},{"id":"8141f138-e3e7-4932-9940-ddfcdfab3b62","acronym":"","url":"https://clinicaltrials.gov/study/NCT04309422","created_at":"2021-01-18T20:53:38.677Z","updated_at":"2024-07-02T16:36:48.235Z","phase":"","brief_title":"Texture Features and PDL1 in CT-PET 18 FDG","source_id_and_acronym":"NCT04309422","lead_sponsor":"University Hospital, Montpellier","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 04/01/2018","start_date":" 04/01/2018","primary_txt":" Primary completion: 10/01/2018","primary_completion_date":" 10/01/2018","study_txt":" Completion: 01/31/2020","study_completion_date":" 01/31/2020","last_update_posted":"2020-03-18"},{"id":"9d759b1e-1179-43f0-84f0-2e00510ccf08","acronym":"","url":"https://clinicaltrials.gov/study/NCT02840994","created_at":"2021-01-18T13:56:43.083Z","updated_at":"2024-07-02T16:36:49.478Z","phase":"Phase 1","brief_title":"A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02840994","lead_sponsor":"Bavarian Nordic","biomarkers":" ALK • ROS1 • CEACAM5","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression","tags":["ALK • ROS1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK translocation • CEACAM5 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Panvac-VF (falimarev/inalimarev)"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-02-27"}]